|
|
 |
Total PSA IRMA Test | | | General Information | |
| Vendor | | Diagnostic Systems Laboratories, Inc. | | Item | | Total PSA IRMA Test | | Features | | Requires only 50 µL sample to test
No sample pretreatment required
Incubation is 2 hrs + 1 hr on shaker at RT | | Approval | | For In Vitro Diagnostic Use | | Product Number | | DSL-9700-5 | | Sensitivity | | 0.013 ng/mL | | Storage / Stability | | 8 wks | | Pricing |  | Inquire |
| | Product Description | |
| Prostate-Specific Antigen (PSA) derives its name from its first known site of origin, the prostate gland. The majority of PSA circulates bound to anti-chymotrypsin (PSA-ACT) and other compounds. Serum concentrations of PSA are elevated in patients with prostate cancer, benign prostatic hypertrophy (BPH) and prostatitis [1-3]. In addition, PSA serum levels appear to correlate with the volume and clinical stage of prostate cancer [1,4]. Selective determination of the various forms of PSA (i.e. free PSA, PSA-ACT complex and total PSA) may be useful to distinguish BPH from untreated prostate cancer. The ratio of free PSA to PSA-ACT is lower in untreated prostate cancer patients than in normal individuals or in patients with BPH. Thus, in patients with PSA in the 4 to 10 mg/L range (diagnostic gray zone), determination of free PSA fractions as a percentage of the total levels (i.e. the free PSA percentage) has been proposed as a means to improve discrimination between BPH and untreated prostate cancer in patients [1,3,5,6].
It has been found that PSA is not specific to the prostate. There are a number of non-prostatic sources of PSA, such as the periurethral glands, breast cancer tissues, breast fluids, amniotic fluid and other [7]. Urinary PSA has also been measured in women with hyperandrogenic syndromes such as polycystic ovarian syndrome [8].
- Vessella RL. Clin Chem 39:2035, 1993.
- Papsidero LD, et al. Cancer Res 40:2428, 1980.
- Kuriyama M, et al. Cancer Res 40:4658, 1980.
- Graves HCB. Clin Chem 38:1930, 1992.
- Lilja H, et al. Clin Chem 37:1618, 1991.
- Stenman UH, et al. Cancer Res 51:222, 1991.
- Diamandis EP & Yu H. Urol Clin North Am 24:275-282, 1997.
- Obiezu CV et al. J Clin Endocrinol Metab 86:1558-1561, 2001.
| |
|
 |
| Diagnostic Systems Laboratories, Inc. | | Customer Service: (800) 231-7970 | | Web site: http://www.dslabs.com | | Please mention Medcompare.com when you contact the vendor. |
| NOTE: Medcompare disclaims any information on this site. The information found on Medcompare (Drug Guide, Product Listings and otherwise) is intended for use by medical professionals. This information is not intended to replace the information, advice or instructions from a medical doctor. Pricing information is approximate, actual prices may vary. |
|
|
